On the day of this milestone, Biocon . outperformed its sector by 0.88%, continuing a positive trend with gains over the last two consecutive sessions. The stock has delivered a 3.04% return during this period, signalling sustained upward movement. Trading above all key moving averages — including the 5-day, 20-day, 50-day, 100-day, and 200-day averages — Biocon . demonstrates robust technical strength.
Over the past year, Biocon . has recorded a total return of 30.28%, significantly outpacing the Sensex’s 9.72% performance over the same timeframe. The stock’s 52-week low was Rs.290.80, highlighting the extent of its price appreciation over the last twelve months.
Our current Stock of the Month is out! This mid-cap from Pharmaceuticals & Biotechnology emerged as the single best opportunity from our elite universe. Get the details now!
- Current monthly selection
- Single best opportunity
- Elite universe pick
Biocon .’s market capitalisation grade stands at 2, reflecting its position within the mid-cap segment of the Pharmaceuticals & Biotechnology industry. The Mojo Score for the stock is 57.0, with a recent adjustment in evaluation noted on 13 Oct 2025, moving from a previous grade of Sell to Hold. This revision aligns with the stock’s recent price action and market dynamics.
In contrast, the broader market has experienced some volatility. The Sensex opened 91.42 points higher but later declined by 185.60 points, trading at 84,856.77, down 0.11%. Despite this, the Sensex remains close to its own 52-week high of 85,290.06, just 0.51% away. The index is currently trading above its 50-day moving average, which itself is positioned above the 200-day moving average, indicating a generally bullish technical setup.
Biocon .’s recent price strength is supported by its ability to maintain levels above all major moving averages, a technical indicator often associated with sustained momentum. This technical positioning may have contributed to the stock’s ability to reach the Rs.424.95 level, marking its highest price point in the last 52 weeks.
Is Biocon . your best bet? SwitchER suggests better alternatives across peers, market caps, and sectors. Discover stocks that could deliver more for your portfolio!
- Better alternatives suggested
- Cross-sector comparison
- Portfolio optimization tool
Examining the stock’s trajectory, the 52-week high of Rs.424.95 represents a significant benchmark for Biocon ., reflecting a price level that has not been surpassed in the past year. This milestone is particularly noteworthy given the stock’s steady climb from its 52-week low of Rs.290.80, illustrating a price range expansion of approximately 46.1% over the period.
Biocon . operates within the Pharmaceuticals & Biotechnology sector, which has seen varied performance across its constituents. The stock’s ability to outperform its sector by 0.88% on the day of the new high suggests relative strength within its industry grouping. This outperformance is further emphasised by the stock’s positive returns over the last two sessions, contrasting with the broader market’s modest decline.
Overall, Biocon .’s attainment of a new 52-week high at Rs.424.95 is a clear indicator of its recent price momentum and technical resilience. The stock’s position above all key moving averages and its outperformance relative to sector and benchmark indices provide a factual basis for understanding the current market dynamics surrounding this pharmaceutical and biotechnology player.
Get 2 full years of MojoOne Premium for only Rs. 12,999. Subscribe for 1 year and we'll add another year FREE. Offer valid for a limited time. Start Saving Now →
